Sunshine Lake Pharma Co Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of multiple sclerosis, psoriasis, rheumatoid arthritis, atopic dermatitis, scleroderma, lupus nephritis, systemic lupus erythematosus and ulcerative colitis, among others.
Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 (FGF21)/glucagon-like peptide-1 (GLP-1) receptor agonist currently in a phase II study for type 2 diabetes.
Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 (FGF21)/glucagon-like peptide-1 (GLP-1) receptor agonist currently in a phase II study for type 2 diabetes.
Sunshine Lake Pharma Co Ltd. has identified pyrimidopyridine compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Research at Sunshine Lake Pharma Co. Ltd. has led to the identification of Toll-like receptor 8 (TLR8) agonists reported to be useful for the treatment of multiple sclerosis, allergy, cancer, influenza, hepatitis B virus, hepatitis C virus, herpes virus, and HIV infections, among others.
Pyrimidopyridine derivatives acting as GTPase KRAS G12D inhibitors have been reported in a Sunshine Lake Pharma Co. Ltd. patent as potentially useful for the treatment of cancer.
Sunshine Lake Pharma Co. Ltd. has divulged benzazepine heterocyclic compounds acting as nuclear receptor RORγT (T cell-specific isoform 2) agonists reported to be useful for the treatment of cancer, rheumatoid arthritis, psoriasis, asthma, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease and Kawasaki disease, among others.
